1. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
- Author
-
Anwar R. Padhani, Sadhna Verma, Christopher R. Porter, Stefano Fanti, Jonathan A. Coleman, Jeffrey Kamradt, R. Bryan Rumble, Jorge Oldan, Andrew B. Rosenkrantz, Peter L. Choyke, Aytekin Oto, Matthew I. Milowsky, Westley Sholes, Andrei S. Purysko, H. Alberto Vargas, Ashesh B. Jani, Baris Turkbey, Kirk A. Keegan, Glenn Bauman, Adam T. Froemming, Martin G. Pomper, Edouard J. Trabulsi, Peter A. Pinto, Matthias Eiber, Heinz Peter Schlemmer, Suneil Jain, Thomas A. Hope, Hossein Jadvar, Daniel Margolis, Michael J. Morris, and Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ, Froemming A, Oto A, Purysko A, Milowsky MI, Schlemmer HP, Eiber M, Morris MJ, Choyke PL, Padhani A, Oldan J, Fanti S, Jain S, Pinto PA, Keegan KA, Porter CR, Coleman JA, Bauman GS, Jani AB, Kamradt JM, Sholes W, Vargas HA.
- Subjects
Oncology ,Diagnostic Imaging ,Male ,Cancer Research ,medicine.medical_specialty ,MEDLINE ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Prostate ,Internal medicine ,Positron Emission Tomography Computed Tomography ,Medicine ,Humans ,prostate cancer, asco ,business.industry ,Prostatic Neoplasms ,Guideline ,medicine.disease ,Magnetic Resonance Imaging ,Prostatic Neoplasms, Castration-Resistant ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business ,Tomography, X-Ray Computed - Abstract
PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
- Published
- 2020
- Full Text
- View/download PDF